UroGen Pharma presents 36-month ENVISION trial data

UroGen Pharma (URGN) announced a 36-month duration of response of 64.5% by Kaplan-Meier estimate in patients who achieved a complete response at three months in the pivotal Phase 3 ENVISION trial of Zusduri for intravesical solution. “The ENVISION 36-month DOR data reinforce ZUSDURI’s potential to shift the treatment paradigm for recurrent LG-IR-NMIBC,” said Mark Schoenberg, chief medical officer, UroGen. “By delivering durable responses without maintenance therapy, ZUSDURI provides an opportunity to move beyond the cycle of repeated surgical interventions and toward a more durable, lower-burden treatment approach over time.”